Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 18,606

Document Document Title
WO/2019/051755A1
Disclosed is a method for preparing tetraethylammonium tetrafluoroborate, comprising the following steps: adding 25-35 parts of a fluoroboric acid aqueous solution to a reactor made of a polytetrafluoroethylene material, at 40ºC-50ºC, ...  
WO/2019/053626A1
The present invention relates to domiphen bromide derivatives of formula (I), which are useful as preservatives and antimicrobials and as antiseptics.  
WO/2019/046931A1
Compounds of general formula IA, IB and IC outlined below, including pharmaceutically acceptable salts, solvates and hydrates thereof. Such compounds and pharmaceutical compositions comprising them may be used in medical conditions invol...  
WO/2019/048458A1
The present application relates to compounds of formulas (I) and (II), to methods for the production thereof, and to the use thereof in electronic devices.  
WO/2019/048590A1
The present invention relates to a carbonic acid adduct (CAA) comprising carbonic acid, at least one amine, and optionally at least one salt, said adduct being producible by a method comprising the following steps: a) providing a solutio...  
WO/2019/050153A1
The present invention provides a novel phenanthrene compound and an organic light emitting device using the same.  
WO/2019/048443A1
The present application relates to compounds of formula (I), to methods for the producing thereof, and to the use thereof in electronic devices.  
WO/2019/041961A1
Provided are a transparent nucleating agent, a preparation method therefor and the use thereof, wherein the transparent nucleating agent comprises a compound represented by formula (1) and a derivative thereof; the method comprises: brin...  
WO/2019/046591A1
Disclosed herein are methods for treating cancer comprising administering CAR-modified immune cells and at least one Retinoic Acid Receptor agonist.  
WO/2019/044542A1
A purpose of the present invention is to provide an organic thin film light-emitting element having improved light-emitting efficiency and durable service life. In order to achieve this purpose, the compound of the present invention has ...  
WO/2019/044585A1
Provided is a nucleus hydrogenation reaction catalyst having a catalytic activity superior to conventional ruthenium catalysts in a nucleus hydrogenation reaction of an aromatic compound in which at least one amino group is bonded to an ...  
WO/2019/044584A1
Provided is a nucleus hydrogenation reaction catalyst having a catalytic activity superior to conventional ruthenium catalysts in a nucleus hydrogenation reaction of an aromatic compound in which at least one amino group is bonded to an ...  
WO/2019/042301A1
The present invention provides a new class of (E)-α,β-unsaturated amide compounds represented by formula I, and also relates to methods for preparing such compounds and the pharmaceutical uses thereof. The compounds have the effect of ...  
WO/2019/037791A1
Provided are a long-acting rasagiline prodrug and a preparation method and use thereof. The long-acting rasagiline prodrug has a structure of formula (I), wherein, T is selected from (II) or not present; R1 and R2 are each independently ...  
WO/2019/037161A1
A method for synthesizing a key clofazimine intermediate N-(4-chlorphenyl)-1,2-phenylenediamine. The method comprises: 1) using o-fluoronitrobenzene and p-chloroaniline as raw materials and an organic base as a catalyst for condensation ...  
WO/2019/038764A1
The present invention relates to lyso-diacylglyceryltrimethylhomoserine (lyso- DGTS) or derivatives thereof for use in the treatment of atherosclerotic cardiovascular disease, and further provides particular such lyso-DGTS derivatives.  
WO/2019/037438A1
The present invention relates to a monomeric pentamethylenediamine adipate of a bio-based material nylon 56, a crystal structure thereof, a crystalline powder thereof, and a preparation method therefor. The pentamethylenediamine adipate ...  
WO/2019/040463A1
Provided are novel compounds of Formulas (I) and (II), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful as dual FKBP12/FKABP inhibitors. Also provided are pharmaceutical compositions co...  
WO/2019/036374A1
Described herein are compounds, or pharmaceutically acceptable salts thereof, of the following formula (I). The compounds are useful for treating inflammatory and autoimmune diseases.  
WO/2019/031454A1
Provided are: a high-purity arylsulfonic acid amine salt vinyl monomer which has both of excellent storage stability and amphipathicity such that the monomer is soluble in both of water and an organic solvent and which is an extremely in...  
WO/2019/030187A1
The invention discloses a method for the preparation of substituted 4-(heptafluoro-2-propyl) anilines by reaction of 2-bromoheptafluoropropane with anilines in the presence of sodium dithionite, in a solvent and in the presence of a cata...  
WO/2019/030189A1
The present invention relates to a process to convert cyclic alkylene ureas into their corresponding alkylene amines by reaction with an amine compound chosen from the group of primary amines or secondary amines that have a higher boilin...  
WO/2019/030197A1
The present invention relates to a process to prepare propylene amines of the formula NH2-(A-NH-)pR, wherein R is a hydrogen atom or an alkyl group, p is at least 1 when R is an alkyl group, and at least 2 when R is a hydrogen atom, or d...  
WO/2019/030194A1
The invention relates to a process for manufacturing polyethyleneannine compounds selected from the group of polyethyleneamines and hydroxyethylethyleneamines comprising the steps of - in an adduction step providing a CO2 adduct of a sta...  
WO/2019/030188A1
The present invention relates to a process to convert the cyclic monourea of ethylene amine compounds (U-EA) into ethylene amine compound (EA) by performing a reactive separation step using a reaction mixture containing the cyclic monour...  
WO/2019/032743A1
The present disclosure relates generally to eukaryotic initiation factor 2B modulators, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers or prodrug thereof, and methods of making and using thereof.  
WO/2019/030196A1
The invention relates to a process for converting one or more cyclic ethylene ureas into corresponding ethylene amines and carbon dioxide. In the process, water is contacted with one or more cyclic alkylene urea compounds comprising one ...  
WO/2019/030193A1
The invention pertains to a process for converting cyclic alkyleneureas into their corresponding alkyleneamines, comprising - in a first step converting cyclic alkyleneureas into their corresponding alkyleneamines by reacting cyclic alky...  
WO/2019/024924A1
The present invention relates to an amine compound for inhibiting semicarbazide-sensitive amine oxidase (SSAO) and/or vascular adhesion protein-1 (VAP-1) inhibitors and use thereof in medicine, and further relates to a pharmaceutical com...  
WO/2019/026994A1
The present invention provides a pharmaceutical composition for the treatment or prevention of cognitive function diseases or disorders, wherein the pharmaceutical composition contains a compound represented by formula (I), an enantiomer...  
WO/2019/020654A1
The present application relates to a spirobifluorene derivative of a specific formula (I) which is suitable for use in electronic devices.  
WO/2019/021836A1
The present invention relates to a vapor deposition raw material for manufacturing a platinum thin film or a platinum-compound thin film by a vapor deposition method. This vapor deposition raw material comprises an organoplatinum compoun...  
WO/2019/022251A1
A (poly)amine compound represented by formula (0): (in formula (0), RX represents a C1-70 2nA-valent group or a single bond; R1A each independently represent an optionally substituted C1-30 alkyl group, an optionally substituted C6-30 ar...  
WO/2019/020029A1
Disclosed are a gem-difluoroethyl substituted stilbene and diphenylethane derivatives, and a preparation method therefor and the use thereof. The present invention conducts a chemical structure modification with a gem-difluoroethyl at th...  
WO/2019/023264A1
Aspects of the present disclosure include G6PD-modulating agents and methods for modulating a glucose-6-phosphate dehydrogenase (G6PD) in a sample using such agents. A G6PD-modulating agent can be dimeric and include two terminal carbocy...  
WO/2019/018562A1
Provided herein are compounds, compositions and methods of using the compounds and compositions for the treatment of diseases modulated, as least in part, by AhR. The compounds are represented by formulae Formula (I), (II), (III), (iv): ...  
WO/2019/017336A1
This compound is represented by general formula (1). In general formula (1), R1 and R2 each independently denote a hydrogen atom, a methyl group or an ethyl group, and the sum of the number of carbon atoms in the group denoted by R1 and ...  
WO/2019/014651A1
The present invention relates to cyclobenzaprine analogs and amitryptilene analogs, including deuterated forms useful for treatment or prevention of symptoms associated with post-traumatic stress disorder.  
WO/2019/011711A1
The present invention relates to a to prepare ethylene amines of the formula NH2-(C2H4-NH-)pH wherein p is at least 2, or derivatives thereof wherein one or more units -NH-C2H4-NH- may be present as a cyclic ethylene urea unit (I) compri...  
WO/2019/011708A1
The invention pertains to a process to prepare ethylene amines with n ethyleneunits and n+1 amine groups wherein n is at least 4, or urea derivatives of said ethylene amines, by reacting an ethanolamine-functional compound, an amine-func...  
WO/2019/011710A1
The present invention relates to a process to prepare ethyleneamines of the formula NH2-(C2H4-NH-)PI-I wherein p is at least 3, or derivatives thereof wherein one or more units -NH-C2H4-NH- may be present as a cyclic ethylene urea unit o...  
WO/2019/013709A1
Disclosed herein is a zero-dimensional hybrid organic-inorganic perovskite material of Formula (I) wherein A contains at least one aromatic or heteroaromatic ring, M is selected from Ge, Pb, Sn, Mn, Cu, Co, and Eu, and X is a halide or p...  
WO/2019/010999A1
Provided are a quantum dot and a quantum dot preparation method. The method comprises the following steps: preparing a quantum dot solution, preparing an ion-containing organic ligand precursor, and adding the ion-containing organic liga...  
WO/2019/012349A1
Embodiments of the present disclosure describe carbocyclic pseudo Tröger's base (CTB) amines. Embodiments of the present disclosure further describe microporous polymers derived from pseudo CTB amines, including, but not limited to, pol...  
WO/2019/002190A1
The present application relates to a spirobifluorene derivative of a specific formula (I) which is suitable for use in electronic devices.  
WO/2019/004587A1
The present disclosure relates to an organic electroluminescent compound and an organic electroluminescent device comprising the same. By using the organic electroluminescent compound of the present disclosure, an organic electroluminesc...  
WO/2018/237140A1
Inhibitors of human topoisomerase II (Top2) are the backbone of numerous cancer chemotherapy regimens. Unfortunately, the onset of toxicity severely limits the utility of these powerful drugs. There is some conservation between human Top...  
WO/2018/234220A1
The present application relates to a polymer containing at least one structural unit of formula (I). The polymer is suitable for use in electronic devices.  
WO/2018/232527A1
The present invention describes complex topical aqueous compositions for the effective delivery of active ingredients such as putrescine and Vitamin C into the skin. These compositions may be used in a variety of cosmetic and therapeutic...  
WO/2018/233633A1
The present invention provides an SSAO inhibitor and an application thereof in preparing a drug for treating a disease related to SSAO. In particular, the present invention provides a compound shown in formula (IV) and a pharmaceutically...  

Matches 1 - 50 out of 18,606